Hokusai-VTE study suggests certain sub-groups of venous thromboembolism patients may need review

September 01, 2013

AMSTERDAM, The Netherlands - In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.

In the landscape of new trials with oral anticoagulants, the Hokusai-VTE findings offer fresh insight into a previously under-represented subgroup of patients with pulmonary embolism (PE), suggesting that treatment for this group might need to be different than for other VTE patients, said lead investigator Harry R. Büller, MD, who presented the findings here at the European Society of Cardiology Congress.

"I think our findings are going to shake things up a little bit," said Dr. Büller, from the Department of Vascular Medicine at Academic Medical Center in Amsterdam.

"What makes this study unique is new insight that there are subgroups in which we might need to revisit what we currently think about the treatment of VTE."

The Hokusai-VTE trial included a broader spectrum of VTE patients compared to those included in other recent oral anticoagulant trials, including a large subgroup (30%) of patients with PE and right ventricular dysfunction, and another subgroup (20%) at high risk for bleeding due to renal impairment and low body weight.

In total, 4921 patients with deep-vein thrombosis and 3319 with pulmonary embolism received initial subcutaneous LMWH therapy and were then randomized to receive either 60 mg of edoxaban daily (30 mg for those at higher risk for bleeding, ie., creatinine clearance 30-50 mL/min or body weight below 60 kg), or warfarin (per standard of care) for 3 to 12 months.

For the primary efficacy endpoint of recurrent symptomatic venous thromboembolism, the study found that edoxaban was non-inferior to warfarin , with the primary endpoint of recurrent symptomatic VTE occurring in 3.2% vs 3.5% respectively (P<0.001 for noninferiority).

However, in the subgroup of patients with pulmonary embolism and evidence of right ventricular dysfunction, efficacy was superior with edoxaban (3.3% vs 6.2%, hazard ratio [HR] 0.52).

For the principal safety outcome of clinically relevant bleeding edoxaban was superior with a rate of 8.5% compared to 10.3% in the warfarin group, (P=0.004 for superiority). This included zero fatal and 5 non-fatal intracranial bleeds with edoxaban compared to 6 fatal and 12 non-fatal intracranial bleeds in the warfarin group.

And among the sub-group of patients ay high risk for bleeding, "by halving the daily dose of edoxaban to 30 mg, efficacy was maintained with significantly less bleeding than observed in the warfarin group," he said. In this high-risk subgroup clinically relevant bleeding occurred in 7.9% of those treated with edoxaban, compared to 12.8% of those treated with warfarin, while superior efficacy was maintained in the edoxaban arm (3.0% vs 4.2%).

Previous trials of oral anticoagulants have not identified these specific sub-groups, noted Dr. Büller.

"It was a nice and surprising finding that the combination of LMWH and edoxoban in the PE group resulted in a highly significant and clinically relevant reduction of about 50% in recurrent disease."

"Our findings are likely to be generalizable. In a global setting," he added. "We included patients with both provoked and unprovoked venous thromboembolism and treatment durations varied from 3 to 12 months at the discretion of the treating physician."

The success of edoxaban compared to warfarin is good news in the quest for simplified treatment of VTE, said Dr. Büller. "The problem with warfarin is that food and alcohol and many, many medications interfere with the level and so therefore you're obliged to do careful laboratory testing every 3 to 4 weeks or even more frequently to measure the INR (international normalised ratio) and adjust the dose," he said. "The great advantage of the new oral anticoagulants is they have very predictable kinetics and dynamics and therefore can be given in a fixed dose and do not need monitoring."

But, along with enthusiasm for oral anticoagulants, there is also growing hope in the field that injectable heparin might also be safely eliminated, thus switching 2 inconvenient therapies for one pill said Dr. Büller.

"Two previous oral anticoagulant studies have omitted LMWH altogether (EINSTEIN PE and AMPLIFY) and were applauded because of the simplicity of just giving pills, " said Dr. Büller, who was the lead author of one of those studies (N Engl J Med 2012; 366: 1287-97).

But, both EINSTEIN PE and AMPLIFY were criticized for under-representing the severely ill sub-groups that make up a large part of the Hokusai-VTE population, he said.

"The whole field was rushing to the conclusion that we could get rid of both heparin, and warfarin, but I think the findings of the Hokusai-VTE study show that in these subgroups it looks like it would be pretty unwise to omit heparin. Our study adjusts that thinking just a little bit, and may start us reconsidering."
-end-
SOURCES OF FUNDING: The study was supported by Daiichi Sankyo.

DISCLOSURES: Harry R. Büller chaired the Hokusai VTE study steering Committee and received compensation for his consultancy and advisory board membership from Daiichi Sankyo.

Notes to editor

About the European Society of Cardiology

The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About ESC Congress 2013

The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. The spotlight of this year's event is "The Heart Interacting with Systemic Organs". ESC Congress 2013 takes place from 31 August to 4 September at the RAI centre in Amsterdam, Netherlands. More information is available from the ESC Press Office at press@escardio.org

European Society of Cardiology

Related Pulmonary Embolism Articles from Brightsurf:

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize.

High risk of deep vein thrombosis and pulmonary embolism in patients with COVID-19
In a systematic review of the worldwide published data on ''Venous thromboembolism (VTE) in COVID-19 patients'', researchers from the Department of Medicine I (MedUni Vienna), provide an in-depth analysis on the risk of VTE in patients hospitalised for COVID-19.

Trial clarifies which patients with acute pulmonary embolism can be managed at home
Patients with acute pulmonary embolism can be selected for home management using the sPESI score or the Hestia criteria, according to results of the HOME-PE trial presented in a Hot Line session today at ESC Congress 2020.1 Principal investigator Professor Pierre-Marie Roy of the University Hospital of Angers, France said: ''The pragmatic Hestia method was at least as safe as the sPESI score for triaging haemodynamically stable pulmonary embolism patients for outpatient care.''

Barriers exist to using risk stratification tools to evaluate pulmonary embolism in the ED
Common barriers exist to the use of risk stratification tools in the evaluation of pulmonary embolism in the emergency department and provide insight into where to focus efforts for future implementation endeavors.

Pulmonary embolism and COVID-19
Researchers at Henry Ford Health System in Detroit say early diagnosis of a life-threatening blood clot in the lungs led to swifter treatment intervention in COVID-19 patients.

Is pulmonary rehab after hospitalization for COPD associated with better survival?
Claims data for nearly 200,000 Medicare patients were used to examine the association between starting pulmonary rehabilitation within 90 days of being hospitalized for chronic obstructive pulmonary disease (COPD) and survival after one year.

Short or long sleep associated with Pulmonary Fibrosis
Scientists have discovered that people who regularly sleep for more than 11 hours or less than 4 hours are 2-3 times more likely to have the incurable disease, pulmonary fibrosis, compared to those that sleep for 7 hours in a day.

Better way to interpret blood tests to diagnose pulmonary embolism
A study led by Hamilton researchers has found a new way to interpret blood test results in patients who are investigated for blood clots in their lungs, a condition known as pulmonary embolism.

Reversed halo signs manifest in septic pulmonary embolism due to IV drug use
According to an article published ahead-of-print in the January 2020 issue of the American Journal of Roentgenology (AJR), reversed halo signs were frequently observed on the chest CT scans of patients with IV substance use disorder-related septic pulmonary embolism.

Treating pulmonary embolism: How safe and effective are new devices?
A new scientific statement from the American Heart Association identifies the risks and benefits of novel interventional devices compared to anticoagulation alone in the treatment of patients with pulmonary embolism.

Read More: Pulmonary Embolism News and Pulmonary Embolism Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.